Mode
Text Size
Log in / Sign up

Computational model shows individualized gamma stimulation outperforms fixed frequency in Alzheimer's simulationComputational model suggests personalized stimulation beats fixed frequency for Alzheimer's

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that computational models suggest individualized gamma stimulation may improve neural synchronization over fixed frequency in Alzheimer's.

This is a computational model study that simulated a population of 200 individuals with Alzheimer's disease to compare individualized gamma frequency stimulation against a fixed 40 Hz stimulation protocol. The primary outcome was the phase-locking value (PLV), a measure of neural synchronization.

The authors found that individualized frequency stimulation yielded a mean PLV of 0.504 +/- 0.009, compared to 0.119 +/- 0.081 for fixed 40 Hz stimulation. This resulted in a 4.2-fold advantage with a Cohen's d effect size of 4.76 (p < 0.001). In a subgroup with an intrinsic gamma frequency below 36 Hz, the fold advantage was 5.3. A sensitivity analysis showed the fold advantage was robust, ranging from 3.8- to 4.0-fold across different levels of stochastic noise (p < 0.001 at all levels).

The authors acknowledge a key limitation: the study population was simulated. The practice relevance noted is that these results provide quantitative computational support for personalized GENUS protocols and could inform the design of next-generation clinical trials.

The findings are limited to a computational model and cannot be interpreted as clinical efficacy in humans. No causal inference between stimulation and cognitive outcomes is possible from this study.

Researchers used a computational model to compare two types of brain stimulation for Alzheimer's disease. The simulation involved 200 cases with brain activity patterns drawn from a realistic clinical distribution. One group received fixed 40 Hz stimulation, while the other received individualized frequency stimulation based on their specific brain rhythms. The results showed that the personalized approach produced a mean phase-locking value of 0.504 compared to 0.119 for the fixed method. This represents a four-fold advantage for the individualized method. The study also found this advantage held up even when noise levels changed in the model. No safety data were reported because this was a computer simulation rather than a human trial. Readers should note that these findings come from a simulated population and do not prove the treatment works in people. The main takeaway is that this model provides quantitative support for designing future clinical trials that measure individual brain frequencies before treatment. This computational work helps plan next-generation studies but does not yet change current patient care.

What this means for you:
This computational model suggests personalized stimulation may be better than fixed frequency for Alzheimer's disease.

Study Details

Sample sizen = 200
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Gamma oscillations (30-100 Hz) are critical for cognitive processing, and their disruption is associated with Alzheimer's disease (AD) and related dementias. Gamma ENtrainment Using Sensory Stimulation (GENUS) therapy applies 40 Hz light and/or sound to restore gamma oscillations, but clinical trials report highly variable responses. Using Kuramoto oscillator models calibrated to human neurophysiology, we demonstrate that frequency mismatch between stimulation frequency and individual intrinsic gamma frequency (IGF) is a critical determinant of entrainment efficacy. A 2 Hz frequency mismatch reduced phase-locking value (PLV) by 43-82%, depending on neural resonance bandwidth, with PLV at mismatch indistinguishable from the finite-sample noise floor, indicating complete absence of stimulus-synchronized oscillation. In a simulated population with IGF drawn from a clinically realistic distribution (mean 35.10 +/- 3.49 Hz, N = 200), fixed 40 Hz stimulation achieved mean PLV of 0.119 +/- 0.081, compared to 0.504 +/- 0.009 for individualized frequency stimulation, corresponding to a 4.2-fold advantage (t(199) = 67.26, p < 0.001, Cohen's d = 4.76). In the clinically relevant subgroup with IGF < 36 Hz (62% of the population), the fold advantage increased to 5.3-fold. Stochastic noise sensitivity analysis confirmed robustness of the fold advantage (3.8- to 4.0-fold across sigma_noise = 0-2.0 rad/s; p < 0.001 at all levels). These findings provide quantitative computational support for personalized GENUS protocols incorporating individual gamma frequency measurement and carry direct implications for the design of next-generation clinical trials.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.